Biotechnological and administration innovations in insulin therapy;Insulinothérapie: Nouvelles molécules et voies d'administration

Medecine/Sciences

Volumn 20, Issue 11, 2004, Pages 986-998

  Verge, Danilo ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO;

BIOTECHNOLOGY; DIABETES CONTROL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; INSULIN TREATMENT; PROTEIN ENGINEERING; REVIEW; TREATMENT OUTCOME;

EID: 8544263816     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20042011986     Document Type: Review

References (45)

1. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-46.
2. Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. UK Prospective diabetes study group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
4. DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-21
5. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry (Honolulu heart program). Diabetes 1987; 36: 689-92.
6. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
7. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-6.
8. Lauritzen T, Faber OK, Binder L. Variation in insulin absorption and blood glucose concentrations. Diabetologia 1979; 17: 291-5.
9. Heinemann L. Variability of insulin absorption and insulin action. Diab Technol Ther 2002; 4: 673-82.
10. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diab Res Clin Pract 1999; 43: 137-42.
11. Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333: 679-82.
12. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
13. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. ([Lys(B28), Pro(B29)])-human insulin. A rapidly absorbed analog of human insulin. Diabetes 1994; 43: 396-402.
14. Pampanelli S, Torlone E, Ialli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995; 18: 1452-9.
15. Ebeling P, Jansson PA, Smith U, et al. Strategies towards improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287-9.
16. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro study group. Diabetes Care 1997; 20: 1827-32.
17. Heller SR, Amiel SA, Mansell P. Effect of fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy. Diabetes Care 1999; 22: 1607-11.
18. Heinemann L, Kapitza C, Starke AAR, Heise T. Time action profile of the insulin analogue B28Asp. Diab Med 1996; 13: 683-7.
19. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
20. Plank J, Witter A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-7.
21. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-8.
22. Home PD, Lindholm A, Riis A, et al. Insulin aspart versus human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomised controlled trial. Diab Med 2000; 17: 762-70.
23. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycaemic control with insulin aspart: a multicenter randomised double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998; 21: 1904-9.
24. Colagiuri S, Heller S, Vaaler S, et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with type 1 diabetes. Diabetologia 2001; 44(suppl 1): A210.
25. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-5.
26. McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and type 2 diabetes mellitus. Drugs 2001; 61: 1599-624.
27. Campbell RK, White JR, Levien T, Baker D. Insulin Glargine. Clin Ther 2001; 23: 1938-57.
28. Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente insulins using the euglycaemic clamp technique. Diabetologia 1999; 42 (suppl 1): A325.
29. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care 2000; 23: 639-43.
30. Strange P, McGill J, Mazzeo M. Reduced pharmacokinetic variability of a novel, long-acting insulin analog. Diabetes 1999; 48 (suppl 1): A103.
31. Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
32. Selam JL, Skeie S, Vague P, et al. Promising results of 6 months treatment with insulin detemir in type 1 diabetic patients. Diabetiologia 2001; 44 (suppl 1) : A15.
33. Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diab Med 1999; 16: 332-8.
34. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002; 16: 475-92.
35. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic human lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25; 883-8.
36. Corsi A, Torre E, Coronel G, et al. Pre-filled insulin pen in newly insulin-treated diabetic patients over 60 years old. Diab Nutr Metab 1997; 10: 78-81.
37. Lawton S, Berg B. Comparative evaluation of FlexPen, a new prefilled insulin delivery system among patients and Healthcare professionals. Diabetes 2001; 50 (suppl 1): A440.
38. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25: 439-44.
39. Bode BW, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001; 24: 69-72.
40. Thompson JS, Duckworth WC. Insulin pumps and glucose regulation. Wld J Surg 2001; 25: 523-6.
41. Heinemann L, Pfützner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Design 2001; 7: 1327-51.
42. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75: 433-8.
43. Hermansen K, Ronnemaa T, Petersen A, Adamson U. Intensive treatment with pulmonary insulin using AERx Insulin Diabetes Management System - a proof of concept trial in type 2 diabetic patients. Diabetes 2002; 51 (suppl 2): 194.
44. Xu HB, Huang KX, Zhu YS, et al. Hypoglycaemic effect of a novel insulin buccal formulation on rabbits. Pharmacol Res 2002; 46: 459-67.
45. Setter SM, Corbett CF, Campbell RK, White JR. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 2000; 34: 1423-31.